Federal Grant Award Summary

New York University School of Medicine received a $179,496 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective July 16, 2026, with completion targeted for June 30, 2028. This research initiative investigates the mechanisms by which viral infections, particularly SARS-CoV-2, drive cardiovascular complications and long-lasting vascular inflammation. The project delivers hypothesis-driven mechanistic research focused on how viral infection reprograms macrophage metabolism and inflammatory responses, accelerating atherosclerosis progression and contributing to post-acute sequelae (PASC). Building on preliminary findings demonstrating preferential SARS-CoV-2 infection of atherosclerotic plaques and altered macrophage function, the research aims to define the pathways linking viral tropism, lipid metabolism, and cardiovascular disease.

The grant supports translational investigation at the intersection of virology, immunology, and cardiovascular pathology, utilizing both in vitro and potentially in vivo models to elucidate foam-cell formation, defective immune clearance mechanisms, and plaque inflammation. Deliverables include mechanistic characterization of viral-induced macrophage dysfunction and data to inform prevention strategies for post-viral cardiovascular complications. This award represents NHLBI's investment in basic and translational research addressing how respiratory viral infections heighten cardiovascular disease risk—a priority area highlighted by the coronavirus pandemic's demonstrated impact on atherosclerotic cardiovascular disease progression and clinical outcomes.